文献速递肝病

抗病毒治疗时代成人慢性乙型肝炎病毒感染不良结局发生率低

Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.
PubMed 文献 · Hepatology · 2021-05-21

在北美多种族成人慢性乙型肝炎病毒(HBV)感染队列中,入组时未接受抗病毒治疗(AVT)且无失代偿、肝细胞癌(HCC)或肝移植(LT)史者前瞻性随访。1418例分析,中位年龄41.1岁,75%为亚裔,基线肝硬化1.5%。随访6641人年后临床结局发生率低,基线肝硬化者4年累积临床结局16%,无肝硬化者7年累积2%(含新发肝硬化)。

要点

  • 北美多种族慢性HBV成人队列随访6641人年,不良结局总体发生率低。
  • 基线肝硬化者4年累积临床结局16%,无肝硬化者7年累积2%(含新发肝硬化)。
  • 数据强调HBsAg清除的获益及早期诊断和治疗以预防肝硬化等并发症的重要性。

核心结论

  • 在这一密切监测的北美成人大型队列中,以非活动性、无肝硬化的慢性HBV感染者为主,不良结局发生率低。
  • 数据强调HBsAg清除的获益以及早期诊断和治疗对预防肝硬化和其他并发症的重要性。

研究设计与样本

  • 前瞻性随访研究,纳入入组时未接受AVT、无失代偿、HCC或LT史的慢性HBV感染成人。
  • 排除已知HIV、丙型肝炎病毒或丁型肝炎病毒(HDV)合并感染者。
  • 随访期间可按标准治疗启动治疗。
  • 共分析1418例参与者。

主要发现

  • 基线特征:51.5%为女性,中位年龄41.1岁,75%亚裔、10%白人、13%黑人,24% HBeAg阳性,1.5%基线肝硬化。
  • 研究期间274例启动治疗,83例出现丙氨酸氨基转移酶 flare,330例初始HBeAg阳性者中118例转为HBeAg阴性,1329例中90例转为HBsAg阴性。
  • 随访6641人年后,8例参与者(基线肝硬化21例中的4例)发生12次临床结局(2例失代偿、5例HCC、2例OLT、3例HBV相关死亡),1397例中19例发生新发肝硬化。
  • 26例参与者中21例首次结局发生在治疗前,均未出现HBsAg阴性,而9例HBeAg阳性者中5例在首次结局时已转为HBeAg阴性。
  • 基线肝硬化者4年累积临床结局百分比为16%,无肝硬化者7年累积百分比为2%(包括新发肝硬化)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Outcomes of persons with chronic hepatitis B virus (HBV) infection in the era of antiviral therapy (AVT) are not well characterized. We determined the incidence and factors associated with clinical outcomes in a multiethnic, North American cohort of adults with chronic HBV infection, who were not on AVT at enrollment. APPROACH AND RESULTS: Adults with chronic HBV infection, not receiving AVT, and without a history of decompensation, HCC, or liver transplantation (LT), were prospectively followed. Participants with known human immunodeficiency virus (HIV), hepatitis C virus, or hepatitis D virus (HDV) coinfection were excluded. During follow-up, treatment could be initiated per standard of care. Clinical outcomes included: incident cirrhosis, decompensation, HCC, OLT, and HBV-related death. Among 1,418 participants analyzed, 51.5% were women, median age was 41.1 years, 75% were Asian, 10% White, 13% Black, 24% HBeAg(+), and 1.5% cirrhosis at baseline. During the study, 274 started treatment, 83 had an alanine aminotransferase flare, 118 of 330 initially HBeAg(+) became HBeAg(-), and 90 of 1,329 became HBsAg(-). After 6,641 person-years follow-up, 8 participants (4 of 21 with baseline cirrhosis) had 12 clinical outcomes (2 decompensation, 5 HCC, 2 OLT, and 3 HBV-related deaths) and 19 of 1,397 had incident cirrhosis. Twenty-one of 26 participants had first outcome before treatment, none had become HBsAg(-), whereas 5/9 HBeAg(+) had become HBeAg(-) at time of first outcome. Cumulative percentage of clinical outcomes was 16% at year 4 in participants with baseline cirrhosis and 2% (including incident cirrhosis) at year 7 in those without. CONCLUSIONS: Incidence of adverse outcomes was low in this closely monitored, large cohort of North American adults with predominantly inactive, chronic HBV without cirrhosis. Our data highlight the benefits of HBsAg loss and the importance of early diagnosis and treatment to prevent cirrhosis and other complications of chronic HBV infection.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Lok AS, Perrillo R, Lalama CM, et al. Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology. 2021. PMID: 32936969. doi:10.1002/hep.31554

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。